Policy changes Backwork has recorded, newest first. The most recent change on record is from October 14, 2026. Changes appear here after Backwork reviews and applies a refresh, so this page can trail the payers’ own sites.
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
83,427 on record
| Recorded | Payer | Policy | Change |
|---|---|---|---|
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | TYRVAYA | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | VYVGART | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | BUDESONIDE/FORMOTEROL | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | SODIUM-GLUOSE CO-TRANSPORTER 2 (SGLT2) PRODUCTS | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | KERENDIA | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | ILEAL BILE ACID TRANSPORTED (IBAT) WITH QUANTITY LIMIT | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | ATOPIC DERMATITIS | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | ACCRUFER WITH QUANTITY LIMIT | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | SMA AGENTS WITH QUANTITY LIMITS | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | PEGFILGRASTIM | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | RITUXAN (RITUXIMAB) & RIABNI (RITUZIMAB) | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | AVASTIN (BEVACIZUMAB) ONCOLOGIC USE | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | METHOTREXATE INJECTABLE STEP THERAPY (THROUGH PREFERRED AGENTS) | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | ORAL PULMONARY ARTERIAL HYPERTENSION (PAH) THERAPY | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | ZEPOSIA | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | ADUHELM (ADUCANUMAB) | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | IMCIVREE (SETMELANOTIDE) | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | ENZYME REPLACEMENT THERAPY | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | ZOKINVY (LONAFARNIB) | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | EVKEEZA (EVINACUMAB) | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | VERQUVO | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | LUPKYNIS (VOCLOSPORIN) | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | HYPEROXALURIA | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | JELMYTO | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | DPP-4 INHIBITORS AND COMBINATIONS | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | FINTEPLA (FENFLURAMINE) | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | DOJOLVI (TRIHEPTANOIN) | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | TEPEZZA | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | ISTURISA | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | LUSPATERCEPT-AAMT (REBLOZYL) | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | COVID TREATMENT | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | PALFORZIA (Peanut (Arachis hypogaea) | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | INTRAVITREAL INJECTIONS FOR RETINAL CONDITIONS | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | ACUTE MIGRAINE THERAPY | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | BEMPEDOIC ACID (NEXLETOL; NEXLIZET) | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | CONJUPRI (LEVAMLODIPINE) | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | VYONDYS 53 (GOLODIRSEN) | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | RILUZOLE PRODUCTS | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | VASCEPA | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | GLP-1 Agonists | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | CONSTIPATION AGENTS | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | SCENESSE (AFAMELANOTIDE) | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | OZOBAX (BACLOFEN) SOLUTION | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | SITE OF CARE | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | ARIKAYCE | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | Amifampridine (FIRDAPSE) | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | DOPTELET | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | PROCYSBI (cysteamine bitartrate delayed release) | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | ZULRESSO | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | EVENITY | New policy |